Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis
European Heart Journal - Cardiovascular Pharmacotherapy · 06.11.2024 · 10 (7) · 614-645
DOI: 10.1093/ehjcvp/pvae064 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 05.09.2024. Verfasst von Bruna Gigante und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Karolinska Institutet, 17177 Stockholm, Sweden. Hauptthemen laut MEDLINE: Fibrinolytic Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 253 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: ZonMw, AstraZeneca, Bristol-Myers Squibb.
Abstract (Originalsprache)
Obesity and underweight are a growing health problem worldwide and a challenge for clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis and/or bleeding. This clinical consensus statement updates a previous one published in 2018, by reviewing the most recent evidence on antithrombotic drugs based on body size categories according to the World Health Organization classification. The document focuses mostly on individuals at the extremes of body weight, i.e. underweight and moderate-to-morbid obesity, who require antithrombotic drugs, according to current guidelines, for the treatment or prevention of cardiovascular diseases or venous thromboembolism. Managing antithrombotic therapy or thromboprophylaxis in these individuals is challenging, due to profound changes in body composition, metabolism and organ function, and altered drug pharmacokinetics and pharmacodynamics, as well as weak or no evidence from clinical trials. The document also includes artificial intelligence simulations derived from in silico pharmacokinetic/pharmacodynamic models, which can mimic the pharmacokinetic changes and help identify optimal regimens of antithrombotic drugs for severely underweight or severely obese individuals. Further, bariatric surgery in morbidly obese subjects is frequently performed worldwide. Bariatric surgery causes specific and additional changes in metabolism and gastrointestinal anatomy, depending on the type of the procedure, which can also impact the pharmacokinetics of antithrombotic drugs and their management. Based on existing literature, the document provides consensus statements on optimizing antithrombotic drug management for underweight and all classes of obese patients, while highlighting the current gaps in knowledge in these complex clinical settings, which require personalized medicine and precision pharmacology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, Karolinska Institutet, 17177 Stockholm, Sweden.
- Department of Cardiology, Danderyds Hospital, 18288 Stockholm, Sweden.
- Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERCV, 28040 Madrid, Spain.
- Division of Clinical Science, Danderyds Hospital, Karolinska Institutet, 18288 Stockholm, Sweden.
- Institute of Clinical Sciences, University of Oslo, NO-0318 Oslo, Norway.
- Department of Cardiology, Oslo University Hospital Ulleval, N-0450 Oslo, Norway.
ORCID-Profile: Bruna Gigante, Juan Tamargo, Stefan Agewall, Dan Atar, Gianluca Campo, Elisabetta Cerbai, Christina Christersson, Dobromir Dobrev, Péter Ferdinandy, Diana A Gorog, Erik L Grove, Andrea Rubboli, Håkan Wallen, Bianca Rocca
Förderung
- ZonMw
- AstraZeneca
- Bristol-Myers Squibb
- Pfizer
- Daiichi Sankyo Company
- AbbVie
- Bayer
- Medtronic
Zitieren
APA
Gigante, B., Tamargo, J., Agewall, S., Atar, D., Ten Berg, J., Campo, G., Cerbai, E., Christersson, C., Dobrev, D., Ferdinandy, P., Geisler, T., Gorog, D. A., Grove, E. L., Kaski, J. C., Rubboli, A., Wassmann, S., Wallen, H., & Rocca, B. (2024). Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis. European Heart Journal - Cardiovascular Pharmacotherapy, 10(7), 614-645. https://doi.org/10.1093/ehjcvp/pvae064
Vancouver
Gigante B, Tamargo J, Agewall S, Atar D, Ten Berg J, Campo G, et al. Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis. European Heart Journal - Cardiovascular Pharmacotherapy. 2024;10(7):614-645. doi:10.1093/ehjcvp/pvae064
BibTeX
@article{Gigante2024,
author = {Gigante, Bruna and Tamargo, Juan and Agewall, Stefan and Atar, Dan and Ten Berg, Jurrien and Campo, Gianluca and Cerbai, Elisabetta and Christersson, Christina and Dobrev, Dobromir and Ferdinandy, Péter and Geisler, Tobias and Gorog, Diana A and Grove, Erik L and Kaski, Juan Carlos and Rubboli, Andrea and Wassmann, Sven and Wallen, Håkan and Rocca, Bianca},
title = {Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2024},
volume = {10},
number = {7},
pages = {614--645},
doi = {10.1093/ehjcvp/pvae064}
}
EUVIMED